Giiant Pharma announced today that it closed a $11 million seed financing round for its drug delivery technology platform.
Montreal-based Giiant develops the Precision Delivery technology platform, which originated from the work from former Merck Frosst scientists, according to a news release. The company designs gut-restricted, tissue-specific, small molecule, drug therapeutics to be delivered through the platform.
Get the full story at our sister site, Drug Delivery Business News.